Schering-Plough - Top 5 layoffs of 2008

Company: Schering-Plough
Layoffs: 5,500

Summary: When a drug makes up 60 percent of your company's profits, any drop in those sales is serious business. The Vytorin safety problems caused Schering-Plough's bottom line to take a major hit, which is why the company decided to cut cut 10 percent of its jobs in April. Part of the 5,500 cuts were also due to acquiring and intergrating Organon BioSciences into the Schering fold. The company said manufacturing plants will close and layers of middle and senior management slashed. Sales and marketing staff will also take cuts, as will R&D. The move will cut costs by $1.5 billion by 2012.

Schering-Plough - Top 5 layoffs of 2008

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.